Now showing items 1-6 of 6

    • Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking. 

      Taggart, D; Andreou, T; Scott, KJ; Williams, J; Rippaus, N; Brownlie, RJ; Ilett, EJ; Salmond, RJ; Melcher, A; Lorger, M (2018-02)
      Inhibition of immune checkpoints programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) on T cells results in durable antitumor activity in melanoma patients. Despite high frequency of melanoma ...
    • CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. 

      Locke, FL; Pidala, J; Storer, B; Martin, PJ; Pulsipher, MA; Chauncey, TR; Jacobsen, N; Kröger, N; Walker, I; Light, S; Shaw, BE; Beato, F; Laport, GG; Nademanee, A; Keating, A; Socie, G; Anasetti, C (2017-03)
      Daclizumab, a humanized monoclonal antibody, binds CD25 and blocks formation of the IL-2 receptor on T cells. A study of daclizumab as acute graft-versus-host disease (GVHD) prophylaxis after unrelated bone marrow ...
    • Characterisation of the immune-related transcriptome in resected biliary tract cancers. 

      Ghidini, M; Cascione, L; Carotenuto, P; Lampis, A; Trevisani, F; Previdi, MC; Hahne, JC; Said-Huntingford, I; Raj, M; Zerbi, A; Mescoli, C; Cillo, U; Rugge, M; Roncalli, M; Torzilli, G; Rimassa, L; Santoro, A; Valeri, N; Fassan, M; Braconi, C (2017-11)
      Although biliary tract cancers (BTCs) are known to have an inflammatory component, a detailed characterisation of immune-related transcripts has never been performed. In these studies, nCounter PanCancer Immune Profiling ...
    • Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. 

      Arce Vargas, F; Furness, AJS; Litchfield, K; Joshi, K; Rosenthal, R; Ghorani, E; Solomon, I; Lesko, MH; Ruef, N; Roddie, C; Henry, JY; Spain, L; Ben Aissa, A; Georgiou, A; Wong, YNS; Smith, M; Strauss, D; Hayes, A; Nicol, D; O'Brien, T; Mårtensson, L; Ljungars, A; Teige, I; Frendéus, B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia; Pule, M; Marafioti, T; Gore, M; Larkin, J; Turajlic, S; Swanton, C; Peggs, KS; Quezada, SA (2018-04)
      With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion ...
    • Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. 

      Arce Vargas, F; Furness, AJS; Solomon, I; Joshi, K; Mekkaoui, L; Lesko, MH; Miranda Rota, E; Dahan, R; Georgiou, A; Sledzinska, A; Ben Aissa, A; Franz, D; Werner Sunderland, M; Wong, YNS; Henry, JY; O'Brien, T; Nicol, D; Challacombe, B; Beers, SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium; Turajlic, S; Gore, M; Larkin, J; Swanton, C; Chester, KA; Pule, M; Ravetch, JV; Marafioti, T; Peggs, KS; Quezada, SA (2017-04-11)
      CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We ...
    • Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. 

      Verkleij, CPM; Broekmans, MEC; van Duin, M; Frerichs, KA; Kuiper, R; de Jonge, AV; Kaiser, M; Morgan, G; Axel, A; Boominathan, R; Sendecki, J; Wong, A; Verona, RI; Sonneveld, P; Zweegman, S; Adams, HC; Mutis, T; van de Donk, NWCJ
      Cell surface expression levels of GPRC5D, an orphan G protein-coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising ...